-
1
-
-
84995370793
-
Analysis of real-world data on overall survival in multiple myeloma patients with ≥3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD
-
Usmani S, Ahmadi T, Ng Y, et al. Analysis of real-world data on overall survival in multiple myeloma patients with ≥3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. Oncologist. 2016;21:1355–1361.
-
(2016)
Oncologist.
, vol.21
, pp. 1355-1361
-
-
Usmani, S.1
Ahmadi, T.2
Ng, Y.3
-
2
-
-
1642348370
-
Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma
-
Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121:482–488.
-
(2004)
Am J Clin Pathol.
, vol.121
, pp. 482-488
-
-
Lin, P.1
Owens, R.2
Tricot, G.3
Wilson, C.S.4
-
3
-
-
1842611807
-
+ B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients
-
+ B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. Leuk Res. 2004;28:469–477.
-
(2004)
Leuk Res.
, vol.28
, pp. 469-477
-
-
Santonocito, A.M.1
Consoli, U.2
Bagnato, S.3
-
4
-
-
0035177850
-
Human CD38: a (r)evolutionary story of enzymes and receptors
-
Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res. 2001;25:1–12.
-
(2001)
Leuk Res.
, vol.25
, pp. 1-12
-
-
Deaglio, S.1
Mehta, K.2
Malavasi, F.3
-
5
-
-
79251570884
-
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors
-
de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186:1840–1848.
-
(2011)
J Immunol.
, vol.186
, pp. 1840-1848
-
-
de Weers, M.1
Tai, Y.T.2
van der Veer, M.S.3
-
6
-
-
84924546237
-
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
-
Overdijk MB, Verploegen S, Bogels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7:311–321.
-
(2015)
MAbs.
, vol.7
, pp. 311-321
-
-
Overdijk, M.B.1
Verploegen, S.2
Bogels, M.3
-
7
-
-
85022333309
-
-
Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. 56th ASH, Annual Meeting and Exposition; December 6–9, 2014; San Francisco, CA
-
® Annual Meeting and Exposition; December 6–9, 2014; San Francisco, CA 2014. Abstract 3474.
-
(2014)
-
-
Lammerts van Bueren, J.1
Jakobs, D.2
Kaldenhoven, N.3
-
8
-
-
84979518325
-
The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fc? receptor-mediated cross-linking
-
Overdijk MB, Jansen JH, Nederend M, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fc? receptor-mediated cross-linking. J Immunol. 2016;197:807–813.
-
(2016)
J Immunol
, vol.197
, pp. 807-813
-
-
Overdijk, M.B.1
Jansen, J.H.2
Nederend, M.3
-
9
-
-
84979519854
-
+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
-
+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128:384–394.
-
(2016)
Blood.
, vol.128
, pp. 384-394
-
-
Krejcik, J.1
Casneuf, T.2
Nijhof, I.S.3
-
10
-
-
84977616350
-
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
-
Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128:37–44.
-
(2016)
Blood.
, vol.128
, pp. 37-44
-
-
Usmani, S.Z.1
Weiss, B.M.2
Plesner, T.3
-
11
-
-
84954377172
-
Daratumumab: first global approval
-
McKeage K. Daratumumab: first global approval. Drugs. 2016;76:275–281.
-
(2016)
Drugs.
, vol.76
, pp. 275-281
-
-
McKeage, K.1
-
12
-
-
85022339957
-
-
EPAR summary for the public. Darzalex daratumumab., Accessed December 21
-
European Medicines Agency. EPAR summary for the public. Darzalex daratumumab. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/004077/WC500207298.pdf. Accessed December 21, 2016.
-
(2016)
-
-
-
14
-
-
84942436321
-
Targeting CD38 with daratumumab monotherapy in multiple myeloma
-
Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373:1207–1219.
-
(2015)
N Engl J Med.
, vol.373
, pp. 1207-1219
-
-
Lokhorst, H.M.1
Plesner, T.2
Laubach, J.P.3
-
15
-
-
84953325096
-
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
-
Lonial S, Weiss B, Usmani S, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387:1551–1560.
-
(2016)
Lancet.
, vol.387
, pp. 1551-1560
-
-
Lonial, S.1
Weiss, B.2
Usmani, S.3
-
16
-
-
84892372742
-
The robust inference for the proportional hazards model
-
Lin DY, Wei LJ. The robust inference for the proportional hazards model. J Am Stat Assoc. 1989;84:1074–1078.
-
(1989)
J Am Stat Assoc.
, vol.84
, pp. 1074-1078
-
-
Lin, D.Y.1
Wei, L.J.2
-
18
-
-
79952911779
-
Ten years of improvement in the management of multiple myeloma: 2000–2010
-
Harousseau JL. Ten years of improvement in the management of multiple myeloma: 2000–2010. Clin Lymphoma Myeloma Leuk. 2010;10:424–442.
-
(2010)
Clin Lymphoma Myeloma Leuk.
, vol.10
, pp. 424-442
-
-
Harousseau, J.L.1
-
19
-
-
41949130070
-
Improved survival in multiple myeloma and the impact of novel therapies
-
Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520.
-
(2008)
Blood.
, vol.111
, pp. 2516-2520
-
-
Kumar, S.K.1
Rajkumar, S.V.2
Dispenzieri, A.3
-
20
-
-
67349240834
-
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)
-
Kastritis E, Zervas K, Symeonidis A, et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia. 2009;23:1152–1157.
-
(2009)
Leukemia.
, vol.23
, pp. 1152-1157
-
-
Kastritis, E.1
Zervas, K.2
Symeonidis, A.3
-
21
-
-
84856719479
-
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study
-
Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26:149–157.
-
(2012)
Leukemia.
, vol.26
, pp. 149-157
-
-
Kumar, S.K.1
Lee, J.H.2
Lahuerta, J.J.3
-
22
-
-
85022331480
-
-
Adjusted comparisons suggest daratumumab is associated with prolonged survival compared with standard of care therapies in patients with heavily pre-treated and highly refractory multiple myeloma. Poster presented at the 58th American Society of Hematology Annual Meeting & Exposition, San Diego, CA, December 3–6
-
Kumar S, Durie B, Su Z, et al. Adjusted comparisons suggest daratumumab is associated with prolonged survival compared with standard of care therapies in patients with heavily pre-treated and highly refractory multiple myeloma. Poster presented at the 58th American Society of Hematology Annual Meeting & Exposition, San Diego, CA, December 3–6, 2016.
-
(2016)
-
-
Kumar, S.1
Durie, B.2
Su, Z.3
|